Summary
Stryker Corporation (SYK) has filed a Form 8-K to provide updated segment reporting information. This filing details a change in organizational structure initiated in the first quarter of 2026, which combines the orthopaedic instruments portfolio from its Instruments business with the Mako and enabling technologies portfolio from its Other Orthopaedics business to form a new 'Ortho Tech' business. This strategic move aims to simplify the customer experience and accelerate market speed through focused innovation. While this reorganization creates a new internal business unit, Stryker will continue to report its financial results under its two existing reportable segments: MedSurg and Neurotechnology, and Orthopaedics. The primary purpose of this 8-K is to comply with SEC regulations requiring the recasting of prior period financial statements in certain future filings (like registration statements or proxy statements) to reflect these segment changes. Investors should note that this filing does not restate previously issued financial statements or update the Management's Discussion and Analysis from the 2025 10-K, but provides recast information for the year ended December 31, 2025, as detailed in Exhibit 99.1.
Key Highlights
- 1Stryker has reorganized its business structure, creating a new 'Ortho Tech' business unit.
- 2The 'Ortho Tech' business combines orthopaedic instruments with Mako and other enabling technologies.
- 3The company's reportable segments remain unchanged: MedSurg and Neurotechnology, and Orthopaedics.
- 4This 8-K filing is primarily to recast prior financial information to align with the new segment reporting structure.
- 5The recast financial information pertains to the year ended December 31, 2025, and is provided in Exhibit 99.1.
- 6This filing does not represent a restatement of previously issued financial statements.
- 7Investors should refer to the 2025 10-K and the Q1 2026 10-Q for comprehensive financial details and operational updates.